非选择性β受体阻滞剂与肝硬化失代偿及死亡率:一项全国队列研究
该研究在无既往失代偿的Child-Turcotte-Pugh A级肝硬化退伍军人中,采用活性对照新用药者设计比较卡维地洛与选择性β受体阻滞剂,发现卡维地洛与较低的肝硬化失代偿风险及失代偿/肝病相关死亡复合结局风险相关。
要点
- 在无既往失代偿的CTP A级肝硬化患者中,卡维地洛较选择性β受体阻滞剂与更低的失代偿风险相关。
- 卡维地洛还与小较低的肝硬化失代偿/肝病相关死亡复合结局风险相关。
- 亚组分析显示,在无HCV病毒血症、较高CTP分级和血小板计数、较年轻及酒精性肝病病因者中,卡维地洛与主要结局风险降低相关。
核心结论
- 在无既往失代偿的CTP A级肝硬化退伍军人中,卡维地洛较选择性β受体阻滞剂与更低的肝硬化失代偿及失代偿/肝病相关死亡复合结局风险相关。
- 作者认为,仍持续需要无创识别可能从非选择性β受体阻滞剂中获益以预防肝硬化失代偿的患者。
研究设计与样本
- 采用活性对照新用药者设计的全国队列研究,纳入无既往失代偿的CTP A级肝硬化退伍军人。
- 卡维地洛新用药者123例,选择性β受体阻滞剂新用药者561例,随访至多3年。
- 采用逆概率治疗加权平衡人口学和临床混杂因素,主要分析为模拟意向治疗的逆概率治疗加权Cox模型。
主要发现
- 在模拟意向治疗分析中,卡维地洛较选择性β受体阻滞剂与更低的任何肝硬化失代偿风险相关(HR 0.59,95% CI 0.42-0.83)。
- 在模拟意向治疗分析中,卡维地洛较选择性β受体阻滞剂与更低的肝硬化失代偿/肝病相关死亡复合结局风险相关(HR 0.56,95% CI 0.41-0.76)。
- 在模拟按治疗分析中,卡维地洛较选择性β受体阻滞剂的肝硬化失代偿风险为HR 0.55(95% CI 0.33-0.94),复合结局风险为HR 0.62(95% CI 0.38-1.01)。
- 亚组分析显示,在无HCV病毒血症、较高CTP分级和血小板计数、较年轻及酒精性肝病病因者中,卡维地洛与主要结局风险降低相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Little is known about the effectiveness of nonselective beta blockers (NSBBs) in preventing hepatic decompensation in routine clinical settings. We investigated whether NSBBs are associated with hepatic decompensation or liver-related mortality in a national cohort of veterans with Child-Turcotte-Pugh (CTP) A cirrhosis with no prior decompensations. APPROACH AND RESULTS: In an active comparator, new user (ACNU) design, we created a cohort of new users of carvedilol ( n = 123) versus new users of selective beta blockers (SBBs) ( n = 561) and followed patients for up to 3 years. An inverse probability treatment weighting (IPTW) approach balanced demographic and clinical confounders. The primary analysis simulated intention-to-treat ("pseudo-ITT") with IPTW-adjusted Cox models; secondary analyses were pseudo-as-treated, and both were adjusted for baseline and time-updating drug confounders. Subgroup analyses evaluated NSBB effects by HCV viremia status, CTP class, platelet count, alcohol-associated liver disease (ALD) etiology, and age. In pseudo-ITT analyses of carvedilol versus SBBs, carvedilol was associated with a lower hazard of any hepatic decompensation (HR 0.59, 95% CI 0.42-0.83) and the composite outcome of hepatic decompensation/liver-related mortality (HR 0.56, 95% CI 0.41-0.76). Results were similar in pseudo-as-treated analyses (hepatic decompensation: HR 0.55, 95% CI 0.33-0.94; composite outcome: HR 0.62, 95% 0.38-1.01). In subgroup analyses, carvedilol was associated with lower hazard of primary outcomes in the absence of HCV viremia, higher CTP class and platelet count, younger age, and ALD etiology. CONCLUSIONS: There is an ongoing need to noninvasively identify patients who may benefit from NSBBs for the prevention of hepatic decompensation.
引用
- Serper M, Kaplan DE, Taddei TH, et al. Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study. Hepatology. 2022. PMID: 35984731. doi:10.1002/hep.32737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。